Jay Pepose - 08 Apr 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Reporting relationship: Director
Issuer ticker: IRD
Reported as of: 08 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Apr 2022, 13:56:32 UTC
Prior SEC filing: 14 Dec 2021
Next SEC filing: 15 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Emily J. Johns, by Power of Attorney

Key filing fact

Jay Pepose filed Form 4 for Ocuphire Pharma, Inc. (IRD) on 13 Apr 2022.

Key facts

This page summarizes Jay Pepose's Form 4 filing for Ocuphire Pharma, Inc. (IRD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Apr 2022, 13:56.

Change

Previous filing in this sequence was filed on 14 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 08 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $2.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest with respect to 12,500 shares on March 31, 2023, and then with respect to 1,041 shares on the last day of each month from April 2023 through February 2026 and with respect to 1,065 shares at the end of March 2026, subject to the Reporting Person's continuing service through each applicable vesting date.